09:45 AM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our 12-month target price of $272, valuing AJG shares at 23.8x our 2025 adjusted EPS estimate of $11.45 and at 26.8x our 2024 EPS estimate of $10.15 (upped by $0.05), versus the three-year average forward multiple of 24x and a peer average of 23x. JG posted Q1 EPS of $3.49 versus $3.02, which was in line with our $3.50 EPS estimate, but above the $3.41 consensus view on 20% revenue growth, of which 9.4% was organic. This rate of top-line growth beat our estimate of 10% to 15% growth and is above most peers, reflecting AJG's growing presence in an insurance marketplace that remains strong, both in terms of pricing and demand. We now see revenue growth of 15% to 20% in 2024 and growth of 12% to 18% in 2025. We maintain our organic revenue growth forecast of 7% to 10%. We see these strong rates of revenue growth and above-peer rates of organic top-line growth supporting the shares' premium valuation to peers and providing AJG with a catalyst.